Project description
Precision medicine targets glioblastoma
Developing effective precision medicine therapies for glioblastoma (GBM) is a challenge due to the complexity and heterogeneity of this aggressive and lethal form of primary brain tumour. Precision medicine uses targeted therapies tailored to the specific molecular characteristics of individual tumours. However, it is difficult to target GBM, which is known for its heterogeneous tumour microenvironment (TME). In this context, the EU-funded GLIORESOLVE project seeks to extend immunotherapy options to GBM patients, identify novel TME subtype-specific therapeutic targets, develop and optimise preclinical models and test novel drug combinations for precision treatment of GBM based on TME subtype assignment. To this aim, GLIORESOLVE will train 10 innovative and entrepreneurial doctoral candidates through multi-sectoral collaborations in innovative research disciplines.
Objective
Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address European applied biomedical research training needs and will train 10 innovative, entrepreneurial doctoral researchers (DRs). The research objectives of GLIORESOLVE are i) to extend immunotherapy options to IDHwt GBM patients and identify novel tumour microenvironment (TME) subtype-specific therapeutic targets, (ii) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (iii) test novel rationally selected (available) drugs / drug combinations for precision treatment of IDHwt GBM based on TME subtype assignment. Cumulatively, the programme seeks to generate sufficient data to support a post-project Phase 2 clinical trial. The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology. Overall GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease. The GLIORESOLVE network addresses current needs in academia and the private sector to train doctoral researchers in an environment that spans multiple disciplines. Thus, GLIORESOLVE DRs will be able to navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
Fields of science
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
2 Dublin
Ireland
See on map
Participants (9)
3000 Leuven
See on map
3015 GD Rotterdam
See on map
9052 ZWIJNAARDE - GENT
See on map
75013 Paris
See on map
1445 Strassen
See on map
69117 Heidelberg
See on map
2342 DH Oegstgeest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
38302 Wolfenbuttel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
51373 Leverkusen
See on map
Partners (11)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
15895 Ames (A Coruña)
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
02115 BOSTON MA
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
75013 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3555 Dudelange
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
0450 Oslo
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
51429 Bergisch Gladbach
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
12163 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
WC2B 6AN London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4365 ESCH-SUR-ALZETTE
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
10117 Berlin
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
75006 Paris
See on map